A recent subanalysis of a randomized, double‐blind clinical study using atezolizumab for adjuvant therapy of ccRCC (IMmotion010) revealed that a higher serum KIM‐1 level was a risk factor for poor prognosis, but improved clinical outcomes in the atezolizumab versus placebo group, indicating its association with high tumor immunogenicity [17]. Here, HAVCR1 is linked to nonpapillary renal cell carcinoma.